2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 298

In CCP Positive “At Risk of Rheumatoid Arthritis” Individuals, the Presence of Sub-clinical Synovitis in 4-10joints Universally Results in Clinical Synovitis
Abstract Number: 2423

In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature
Abstract Number: 290

In Psoriatic Arthritis Patients Considered in Remission by Their Rheumatologist, Can Discordance in Disease Activity Assessment Between Patient and Rheumatologist Be Explained by Residual Inflammation as Measured by Ultrasonographic Examination?
Abstract Number: 58

In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets
Abstract Number: 2328

In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use
Abstract Number: 552

In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients
Abstract Number: 113

In Vitro Characterization of the Effect of Cenerimod, a Potent and Selective Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulator, on S1P1 Receptor Expression, Receptor Internalization, and Migration of Primary Human T Cells in the Presence or Absence of Glucocorticoids
Abstract Number: 121

In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition
Abstract Number: 68

Inactivation of Transaldolase and HRES-1/Rab4 Predisposes to Hepatitis in a Mouse Model of Systemic Lupus Erythematosus
Abstract Number: 1514

Inadequate Response Within a Year of Biologic and Oral Synthetic DMARD Treatment Initiation Among Psoriatic Arthritis Patients in the USA Real-World Setting
Abstract Number: 1573

Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort
Abstract Number: 2498

Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study
Abstract Number: 2582

Incidence of Antimalarials-Induced Retinopathy in Inflammatory Rheumatic Diseases, Using OCT and Visual Field Test : A Systematic Review and Meta-analysis
Abstract Number: 925

Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database
Abstract Number: 2715

Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].